Table 3.

Univariate analyses for the assessment of all segments during the SLS, the total score

Variable	SLS test for all segments: non-dominant leg					SLS test for all segments: dominant leg
	na	Cases (%) b	OR c	95% CId	p-valuee	na	Cases (%) b	OR c	95% CId	p-valuee
Division	254	117 (46)	1.43	1.08–1.89	0.01*	254	176 (69)	1.25	0.93–1.6	0.14
Div. 1	89	32 (36)	1			89	56 (63)	1
Div. 2	51	24 (47)	1.58	0.79–3.19		51	37 (73)	1.56	0.74–3.30	0.25
Div. 3	114	61 (54)	2.05	1.16–3.62	0.01*	114	83 (73)	1.58	0.87–2.86	0.13
Age category	254	115 (45)	0.65	0.47–0.91	0.01*	254	176 (69)	0.97	0.69–1.37	0.86
16–19 years	84	47 (56)	1			84	61 (73)	1
20–24 years	99	45 (46)	0.66	0.37–1.18	0.16	99	64 (65)	0.69	0.37–1.30	0.25
25–39 years	71	25 (35)	0.43	0.22–0.82	0.01*	71	51 (72)	0.96	0.48–1.95	0.91
Ankle dorsiflexion f	254	117 (46)	0.97	0.92–1.03	0.39	254	176 (69)	0.92	0.86–0.99	0.03*
Hip strength g	253	117 (46)	0.99	0.98–0.99	0.04*	252	174 (69)	0.99	0.98–0.99	0.02*
A severe injury h	247	114 (46)				247	170 (69)
No	195	100 (51)	1			190	130 (68)	1
Yes	52	14 (27)	0.35	0.18–0.69	0.00*	57	40 (70)	1.09	0.57–2.07	0.80
A time-loss injury i	250	113 (45)				250	174 (70)
No	161	76 (47)				135	88 (65)	1
Yes	89	39 (44)	1	0.52–1.47	0.61	115	86 (75)	1.58	0.91–2.75	0.10
An injury problem j	254	117 (46)	0.87			254	176 (69
No	224	99 (44)	1			214	147 (69)	1
Yes	30	18 (60)	1.89	0.87–4.11	0.11	40	29 (73)	1.20	0.57–2.55	0.63
AFAQ gk	252	115 (46)	0.97	0.93-1.00	0.07	252	174 (69)	0.99	0.96–1.03	0.72
PSS-14 l	252	115 (46)	0.96	0.90–1.03	0.25	252	174 (69)	0.94	0.87–1.01	0.09
PSQI m	252	115 (46)				252	174 (69)
Good sleepers, ≤ 5 points	156	66 (42)	1			156	105 (68)	1
Poor sleepers, ≥ 6 points	96	49 (51)	1.42	0.85–2.37	0.18	96	69 (71)	1.24	0.71–2.17	0.45
GAD-7 n	252	115 (46)	1.07	0.77–1.49	0.70	252	174 (69)	1.36	0.94–1.97	0.11
No anxiety	108	49 (45)	1			108	68 (63)	1
Mild anxiety ≥ 5 points	98	43 (44)	0.94	0.54–1.63	0.83	98	72 (74)	163	0.90–2.95	0.11
Moderate/severe anxiety ≥ 10 points	46	23 (50)	1.20	0.60–2.40	0.60	46	34 (74)	1.67	0.78–2.51	0.19

^*Denotes a statistically significant differences at p ≤ 0.05;

^an: total sample; ^bCases (%): total number of subjects failing on the SLS test, and in brackets, the risk/probability to fail the SLS test expressed in the percentage of the total number of performed Single Leg Squats; ^cOR: odds ratio; ^d95% CI: 95% confidence interval; ^ep-value: probability value; ^fAnkle dorsiflexion: measured with the Weight Bearing Dorsiflexion Lunge Test (WBLT) and calculated with a trigonometric dorsiflexion angle (TA); ^gHip strength: Side-Lying Clamshell (CLAM), body-sized independent measurement; Newton (N)*length of femur (m)/ (Body weight (kg)*height (m)) *100; ^hA severe Injury: One or more time-loss injuries located in the head, lower belly, lower back, pelvis or lower extremities, during season 2021 or earlier, that lasted three months or more; ⁱA time-loss injury: One or more time-loss injuries located in the head, lower belly, lower back, pelvis or lower extremities during season 2021; ^jAn injury problem: An injury problem located in the head, lower belly, lower back, pelvis or lower extremities that did not demand any time-loss from game or training during the four weeks before or during the test occasion; ^kAFAQ: Athletic Fear Avoidance Questionnaire; ^lPSS-14: Perceived Stress Scale 14-item instrument; ^mPSQI: Pittsburgh Sleep Quality Index; ⁿGAD-7: Generalized Anxiety Disorder 7-item scale